Gwendolyn Wu

2 weeks ago | biopharmadive.com | Gwendolyn Wu

Biotechnology startups usually turn to a few tried-and-true options to raise the money they need to develop a new drug. Company founders might get initial financial help from friends, family or an angel investor. Perhaps they’ll apply for grant funding or a spot in a startup accelerator. More often than not, they’ll then rely on venture funding to survive. Siren Biotechnology, a San Francisco-based gene therapy startup, has already done some of that work.

2 weeks ago | finance.yahoo.com | Gwendolyn Wu

Unlock stock picks and a broker-level newsfeed that powers Wall Street. Gwendolyn Wu Thu, May 1, 2025, 2:00 AM 5 min read This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Biotechnology startups usually turn to a few tried-and-true options to raise the money they need to develop a new drug. Company founders might get initial financial help from friends, family or an angel investor.

2 weeks ago | biopharmadive.com | Gwendolyn Wu

Novartis will pay $800 million upfront to acquire Regulus Therapeutics, a San Diego biotechnology company that launched nearly two decades ago with plans to make drugs capable of targeting small strips of nucleic acid known as microRNA. Announced Wednesday, the acquisition will hand the Swiss pharmaceutical firm a drug prospect called farabursen, which recently completed a Phase 1b study in people with autosomal dominant polycystic kidney disease, or ADPKD.

2 weeks ago | finance.yahoo.com | Gwendolyn Wu

Unlock stock picks and a broker-level newsfeed that powers Wall Street. Gwendolyn Wu Wed, Apr 30, 2025, 5:15 AM 2 min read In This Article: This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter.

2 weeks ago | biopharmadive.com | Gwendolyn Wu

Dive Brief:Stealth Biotherapeutics on Tuesday said that a Food and Drug Administration deadline to approve its experimental rare disease drug has passed without a decision, and that the agency hasn’t yet set a new date by which the therapy might be cleared for use in the U.S.The company previously reported in January that the FDA had delayed a verdict on its Barth syndrome drug, elamipretide, so it could review information Stealth submitted following an October meeting of agency advisers.